Press Releases

Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s. Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),   a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized …

Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation Read More »

Havn Life natural health formulations

Havn Life Sciences earns Health Canada approval for natural health product formulations

The initial six approved formulations were developed to enhance human performance and cognitive health Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased …

Havn Life Sciences earns Health Canada approval for natural health product formulations Read More »

Havn Life to supply psychedelic compounds

Havn Life Sciences signs agreement to supply psychedelic compounds for use in research and development to Revive Therapeutics

Havn Life will export naturally derived psilocybin to the United States, for use in IND-enabling studies and future clinical trials under FDA guidelines Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized …

Havn Life Sciences signs agreement to supply psychedelic compounds for use in research and development to Revive Therapeutics Read More »

Havn Life Appoints Dennis Staudt

Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  is pleased to announce that Mr. Dennis Staudt has joined the Company’s Board of Directors. Mr. Staudt has over 35 years’ experience providing sophisticated business advice, having spent most of his career with PricewaterhouseCoopers LLP (“PwC”), including …

Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization Read More »

Havn Life psilocybin application

Havn Life applies for licence to produce and sell psilocybin

The Controlled Drugs and Substances Dealer’s Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive …

Havn Life applies for licence to produce and sell psilocybin Read More »

Havn Life Sciences announces appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, respectively, and the acceleration of Warrants

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having …

Havn Life Sciences announces appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, respectively, and the acceleration of Warrants Read More »

Havn Life joins UK Psychedelics Working Group with leading international scientists

The working group consists of over 35 academics, researchers and policy specialists from four countries. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce …

Havn Life joins UK Psychedelics Working Group with leading international scientists Read More »

Havn Life Sciences Inc. Reports Q1 Financial Statements

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars. First Quarter Results for three months ended July 31, 2020 – Financial highlights: …

Havn Life Sciences Inc. Reports Q1 Financial Statements Read More »

Havn Life Sciences submits range of natural health products to Health Canada

Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive …

Havn Life Sciences submits range of natural health products to Health Canada Read More »

Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange

Havn Life is now cross-listed and trades on both the CSE & FSE  Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it …

Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange Read More »

Scroll to Top